Asset-based health sciences and regenerative medicine company Cardium Therapeutics operates under a business model that involves creating multiple success opportunities without relying on any one technology platform or product type. Focused on acquiring and strategically developing new and innovative biomedical product opportunities and businesses, the company targets opportunities that have the potential to address significant unmet medical needs, are economically viable and have clear pathways to commercialization and partnering. Cardium's business model additionally leverages the company's prowess in late-stage product development, bridging the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium's current portfolio of medical opportunities includes the Tissue Repair Company, Cardium Biologics, and its newly acquired To Go Brands, which is a healthy nutraceutical supplement business. To Go Brands is engaged in the development, marketing, and sale of dietary supplements through established regional and national retailers.
Cardium's lead commercial product, Excellagen, is a topical gel for wound care management that has FDA clearance for marketing and sale in the U.S. The company's lead clinical development product candidate is Generx, a DNA-based angiogenic biologic intended for treating patients with myocardial ischemia due to coronary artery disease.
Cardium considers various corporate development transactions to place its product candidates into larger organizations or with partners that have existing commercialization, sales, and marketing resources and a need for innovative products. As the company's product opportunities and businesses are advanced and corresponding valuations are established, Cardium continues pursuing other cost-effective acquisitions with strong value enhancement potential.
For more information, visit cardiumthx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com